吉西他滨-奥沙利铂联合利妥昔单抗(R-GemOx)作为老年弥漫性大B细胞淋巴瘤一线治疗:单臂、开放标签、2期试验
这项单臂、开放标签、2期试验在江苏省人民医院纳入60例初治老年弥漫性大B细胞淋巴瘤患者,评估R-GemOx方案一线治疗的疗效与安全性。结果显示75%患者达总体缓解,47%达完全缓解,常见3-4级不良事件为血液学毒性和胃肠道反应,无治疗相关死亡。
要点
- R-GemOx方案在老年初治DLBCL患者中总体缓解率75%,完全缓解率47%。
- 常见3-4级不良事件包括血小板减少8%、贫血7%、中性粒细胞减少15%。
- 未报告治疗相关死亡,R-GemOx可能成为老年DLBCL的治疗选择。
核心结论
- R-GemOx方案在老年弥漫性大B细胞淋巴瘤患者中作为一线治疗显示出高疗效和安全性,可能成为老年DLBCL的治疗选择。
研究设计与样本
- 单臂、开放标签、2期临床试验,纳入60例初治、组织学确诊、CD20阳性的弥漫性大B细胞淋巴瘤患者,年龄≥70岁或60-69岁且ECOG体能状态评分≥2分,患者来自江苏省人民医院。
主要发现
- 60例患者中45例(75%)在治疗结束时达到总体缓解,其中28例(47%)达到完全缓解。
- 常见3-4级不良事件为血液学毒性:血小板减少5例(8%)、贫血4例(7%)、中性粒细胞减少9例(15%)。
- 胃肠道并发症包括恶心5例(8%)、呕吐3例(5%)、腹泻1例(2%)。
- 未报告治疗相关死亡。
关键数值与推荐
- R-GemOx方案静脉给药:利妥昔单抗375 mg/m²第0天;吉西他滨1 g/m²第1天;奥沙利铂100 mg/m²第1天;每14天重复一个周期。
- 若中期评估至少达到部分缓解,计划治疗6个周期。
- 主要终点为治疗结束时总体缓解率(完全缓解加部分缓解)。
临床怎么用
- 作者认为R-GemOx方案在老年弥漫性大B细胞淋巴瘤患者中作为一线治疗显示出高疗效和安全性,可能成为老年DLBCL的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx) has shown high efficacy with a low toxicity profile in elderly patients with relapsed and refractory diffuse large B-cell lymphoma. We aimed to evaluate the efficacy, safety, and feasibility of the R-GemOx regimen as a first-line treatment in elderly patients with diffuse large B-cell lymphoma. METHODS: In this single-arm, open-label, phase 2 clinical trial, we enrolled patients with previously untreated, histologically confirmed, CD20-positive diffuse large B-cell lymphoma, aged 70 years or older, or aged 60-69 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or greater. Patients were recruited from Jiangsu Province Hospital (Jiangsu Sheng, China). The R-GemOx regimen was administered intravenously: rituximab 375 mg/m2 on day 0; gemcitabine 1 g/m2 on day 1; and oxaliplatin 100 mg/m2 on day 1. The cycle was repeated every 14 days. Six cycles were planned if the patient achieved at least partial remission after the interim assessment. The primary endpoint was the proportion of patients who achieved an overall response at the end of treatment (defined as complete response plus partial response). Analyses were done by intention to treat. The trial is ongoing but no longer recruiting patients. This study is registered with ClinicalTrials.gov, number NCT01670370. FINDINGS: Between Aug 22, 2012, and Dec 31, 2015, 60 patients were enrolled and included in the study. The median age of the patients was 75 years (IQR 70-80) and 27 (45%) patients had a poor performance status with an ECOG score of 2 or greater. 45 (75%) patients achieved an overall response at the end of the treatment, with 28 (47%) achieving a complete response. Common grade 3-4 adverse events were haematological toxicities (thrombocytopenia in five [8%] patients, anaemia in four [7%], and neutropenia in nine [15%]) and gastrointestinal complications (nausea in five [8%] patients, vomiting in three [5%], and diarrhoea in one [2%]). No treatment-related deaths were reported. INTERPRETATIONS: The R-GemOx regimen shows high efficacy and safety as a front-line treatment in an elderly patient subpopulation and might be a therapeutic option for management of diffuse large B-cell lymphoma in elderly patients. FUNDING: National Natural Science Foundation of China, Jiangsu Province's Medical Elite Programme, Project of National Key Clinical Specialty, National Science & Technology Pillar Program, Jiangsu Provincial Special Program of Medical, and National Science and Technology Major Project.
引用
- Shen QD, Zhu HY, Wang L, et al. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial. Lancet Haematol. 2018. PMID: 29752199. doi:10.1016/S2352-3026(18)30054-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。